• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-08-15

  Zhao and colleagues present a standardized fresh whole-blood stimulation protocol that combines immune challenges with pharmacological metabolism modulation and cytokine quantification. The framework improves comparability across cohort studies while showing that anabolic and catabolic pathway interventions can selectively reshape immune-cell cytokine output.

• AM 281: CB1 Antagonist Workflow for Brain Research

  2026-08-15

  AM 281 provides a receptor-level tool for separating CB1 signaling from upstream endocannabinoid changes in TBI, addiction, and memory assays. This workflow combines controlled formulation, time-resolved tissue collection, behavioral testing, and orthogonal pathway readouts to improve mechanistic confidence.

• YM-155 Hydrochloride: From Assay to Translation

  2026-08-14

  A translational framework for using YM-155 hydrochloride as a selective survivin inhibitor while distinguishing proliferation arrest from true cell killing, strengthening model selection, assay design, and preclinical decision-making.

• Tiamulin Metabolites Across Farm Animal Species

  2026-08-14

  The reference study mapped tiamulin biotransformation across rats, chickens, swine, goats, and cows using UHPLC–quadrupole/time-of-flight mass spectrometry. Its comparative metabolite profiles identify species-dependent pathways and refine potential marker residues for residue surveillance, especially in chickens and swine.

• N4-Acetylcytidine Workflow Guide

  2026-08-13

  N4-Acetylcytidine enables controlled studies of free ac4C nucleoside metabolism, enzyme substrate specificity, and analytical assay performance. This guide distinguishes those use cases from experiments on RNA-incorporated ac4C, with practical preparation, controls, and troubleshooting strategies.

• EZ Cap™ OVA mRNA for Immune Modeling

  2026-08-13

  Use EZ Cap™ OVA mRNA as a defined model-antigen payload for comparing delivery systems, expression conditions, and immune readouts. Its Cap 1 structure and poly(A) tail support reproducible Ovalbumin mRNA expression while enabling practical studies of carrier-associated inflammation.

• SGLT2 Cardioprotection: Class Effect or Drug Effect?

  2026-08-12

  A 2022 mouse study directly compared empagliflozin, dapagliflozin, and ertugliflozin in non-diabetic myocardial ischemia/reperfusion injury. Although all three compounds produced comparable urinary glucose excretion at stoichiometrically equivalent doses, only empagliflozin and dapagliflozin reduced infarct size, implicating drug-specific STAT-3 and PI3K-linked mechanisms rather than SGLT2 inhibition alone.

• Equine Salmonella: TMP–Sulfonamide Synergy

  2026-08-12

  This 1994 study tested trimethoprim and nine sulfonamides against 62 Salmonella strains recovered from horses, using agar dilution and fractional inhibitory concentration analysis. It identified sulfadiazine, sulfachlorpyridazine, and sulfamethoxazole as the most useful partners for trimethoprim, while also showing that resistance patterns varied substantially among isolates.

• Vitamin C, ROS/NF-κB, and Cochlear Cell Senescence

  2026-08-11

  A 2024 Molecular Biology Reports study used D-galactose-treated HEI-OC1 cochlear hair cells to show that vitamin C reduces senescence-associated changes alongside suppression of ROS accumulation and NF-κB activation. N-acetyl-L-cysteine served as a redox-oriented comparator, strengthening the interpretation that oxidative stress pathway modulation contributes to the protective phenotype while leaving in vivo hearing restoration unresolved.

• Ibotenic Acid for Circuit-Resolved Neuroscience

  2026-08-10

  Ibotenic acid is an NMDA receptor agonist used to interrogate excitatory neurotransmission and generate experimentally controlled neural lesions. This guide connects its pharmacology and handling requirements with circuit-level lessons from a landmark mechanical allodynia study, while distinguishing validated evidence from practical assay extensions.

• Losmapimod: A State-Aware p38 MAPK Guide

  2026-08-09

  Losmapimod and GW856553X are more than conventional p38 MAPK pathway probes. This article presents a state-aware framework for interpreting inhibition, kinase dephosphorylation, inflammation signaling modulation, and translational assay design.

• PLGA Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-08-08

  The reference study developed PEI-LSP-RA-PLGA, a double-layer PLGA nanoparticle adjuvant designed to combine sustained release, intestinal targeting, and immune regulation in H9N2-vaccinated chicks. The formulation enhanced serum IgG, intestinal IgA, cytokine responses, lymphocyte differentiation, and intestinal structure, while mechanistic analyses implicated CCR6/CCR9 chemokine signaling and Toll-like, NOD-like, and IgA-production pathways.

• Trelagliptin Succinate: From Glycemia to Bone

  2026-08-07

  Trelagliptin succinate, also known as SYR-472 succinate, offers translational researchers more than a glucose-lowering tool. Its selective DPP-4 inhibition and AMPK–RUNX2 evidence create a disciplined framework for connecting metabolic control with osteoblast biology.

• Elobixibat Hydrate: Precision Modulation of Gut Motility and

  2026-08-07

  Explore how Elobixibat hydrate, a leading ileal bile acid transporter inhibitor, enables precision modulation of gut motility and metabolic pathways. This article offers a mechanistic deep dive, unique translational insights, and protocol guidance distinct from prior reviews.

• GTP Solution (100 mM): Enabling Precision mRNA Synthesis for

  2026-08-06

  Explore how GTP Solution (100 mM) empowers high-fidelity mRNA synthesis for advanced bladder cancer research. This article delivers a unique, in-depth analysis of guanosine-5'-triphosphate's scientific and practical impact, protocol optimization, and translational implications.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page